Evercore ISI Boosts Kiniksa Pharmaceuticals (NASDAQ:KNSA) Price Target to $35.00

Kiniksa Pharmaceuticals (NASDAQ:KNSA) had its price objective lifted by equities researchers at Evercore ISI from $30.00 to $35.00 in a research report issued on Wednesday, Benzinga reports. The firm currently has an “outperform” rating on the stock. Evercore ISI’s price objective would suggest a potential upside of 54.94% from the stock’s previous close.

KNSA has been the subject of a number of other reports. Jefferies Financial Group began coverage on shares of Kiniksa Pharmaceuticals in a research note on Friday, September 13th. They issued a “buy” rating and a $40.00 target price for the company. Wedbush boosted their price objective on shares of Kiniksa Pharmaceuticals from $30.00 to $34.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 23rd. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $34.60.

Kiniksa Pharmaceuticals Stock Down 1.8 %

KNSA stock opened at $22.59 on Wednesday. The business has a fifty day moving average price of $25.57 and a 200 day moving average price of $22.42. Kiniksa Pharmaceuticals has a fifty-two week low of $14.12 and a fifty-two week high of $28.15.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last announced its earnings results on Tuesday, October 29th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.17). The business had revenue of $112.21 million during the quarter, compared to analyst estimates of $111.51 million. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The business’s quarterly revenue was up 67.4% compared to the same quarter last year. During the same quarter last year, the business posted ($0.20) earnings per share. Equities analysts anticipate that Kiniksa Pharmaceuticals will post -0.38 EPS for the current year.

Insider Buying and Selling at Kiniksa Pharmaceuticals

In other news, COO Eben Tessari sold 17,500 shares of Kiniksa Pharmaceuticals stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $26.91, for a total transaction of $470,925.00. Following the completion of the sale, the chief operating officer now owns 119,911 shares in the company, valued at $3,226,805.01. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, COO Eben Tessari sold 17,500 shares of the stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $26.91, for a total value of $470,925.00. Following the transaction, the chief operating officer now directly owns 119,911 shares in the company, valued at $3,226,805.01. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider John F. Paolini sold 60,692 shares of Kiniksa Pharmaceuticals stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $26.12, for a total transaction of $1,585,275.04. Following the sale, the insider now directly owns 52,038 shares of the company’s stock, valued at $1,359,232.56. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 112,692 shares of company stock worth $2,950,315. Company insiders own 54.57% of the company’s stock.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the stock. Essex Investment Management Co. LLC boosted its holdings in Kiniksa Pharmaceuticals by 0.4% during the third quarter. Essex Investment Management Co. LLC now owns 200,516 shares of the company’s stock worth $5,011,000 after buying an additional 717 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in Kiniksa Pharmaceuticals by 5.8% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 20,935 shares of the company’s stock worth $413,000 after acquiring an additional 1,153 shares during the last quarter. SG Americas Securities LLC grew its holdings in Kiniksa Pharmaceuticals by 8.1% during the first quarter. SG Americas Securities LLC now owns 19,160 shares of the company’s stock valued at $378,000 after purchasing an additional 1,435 shares during the period. Linden Thomas Advisory Services LLC increased its stake in Kiniksa Pharmaceuticals by 1.7% in the second quarter. Linden Thomas Advisory Services LLC now owns 118,302 shares of the company’s stock valued at $2,209,000 after purchasing an additional 1,921 shares in the last quarter. Finally, Janney Montgomery Scott LLC raised its holdings in Kiniksa Pharmaceuticals by 7.8% in the first quarter. Janney Montgomery Scott LLC now owns 26,843 shares of the company’s stock worth $530,000 after purchasing an additional 1,940 shares during the period. 53.95% of the stock is owned by institutional investors and hedge funds.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.